Whole Lot Of CDMO Expansion Going On
CDMOs (and sponsors) have invested in expansions and innovation.
Industry expert Ken Ford discusses what that means for cell and gene therapy developers. In October 2022, Outsourced Pharma Live's What’s Driving The Cell & Gene Therapy Outsourcing Capacity Cycle? panelists discussed the identified macro and micro trends impacting deal-making at CDMOs. Exclusive data from BioPlan Associates was also presented. Learn what to be on the lookout for as well as how to prepare and take advantage of (another) "life cycle" in our industry – this time in the cell & gene therapy space.
View the full presentation on-demand here.
Get unlimited access to:
Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.